Benjamin Diamond, MD

A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.

An expert panel compares bispecific antibodies with CAR T-cell therapy and discusses treatment sequencing.

Experts on multiple myeloma discuss the management of adverse effects from bispecific antibodies.

An expert panel discusses bispecific antibodies and their mechanisms of action in the treatment of relapsed/refractory multiple myeloma.

An overview of multiple myeloma treatment options in the frontline and relapsed settings.

Experts on multiple myeloma discuss approaches to laboratory workup and patient monitoring at the time of relapse.

Experts present the case of a 58-year-old patient with IgG kappa multiple myeloma and offer their initial impressions.

Clinical insights on treatment duration and the decision to place patients with newly diagnosed MM on maintenance therapy.

Insights gleaned from the MAIA trial, which researched daratumumab, lenalidomide, and dexamethasone in patients with newly diagnosed MM.

Myeloma experts present the case of a 74-year-old with transplant-ineligible newly diagnosed MM and offer their initial impressions.

An expert panel discusses maintenance therapy for patients with MM and offers insights on how induction therapy impacts treatment options.

Experts on multiple myeloma (MM) discuss factors that determine transplant eligibility for patients who are newly diagnosed.

An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.

A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.